| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Integrating liver and heart health: Cardiovascular risk reduction in patients with metabolic-associated steatotic liver disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Thang Viet Luong, Hoa Tran, Bich Ngoc Hoang Thi, Hung Minh Vu, The Trung Le, Tien Thi Le, Huyen Trang Tran Thi, Hung Minh Nguyen, Thang Chi Doan, Binh Anh Ho, Tien Anh Hoang and Hai Nguyen Ngoc Dang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hai Nguyen Ngoc Dang, Lecturer, MD, Researcher, Faculty of Medicine, Duy Tan University, 254 Nguyen Van Linh, Da Nang 550000, Viet Nam. ngochai123dc@gmail.com |
| Key Words |
Metabolic-associated steatotic liver disease; Cardiovascular disease; Insulin resistance; GLP-1 receptor agonists; SGLT2 inhibitors; Statins; Bariatric surgery; Multidisciplinary care; Emerging therapies |
| Core Tip |
Metabolic-associated steatotic liver disease (MASLD), a leading global liver disorder, is strongly linked to cardiovascular disease (CVD) through shared pathways including insulin resistance, dyslipidemia, and systemic inflammation. This review examines the bidirectional relationship between MASLD and CVD, highlighting CVD as the primary cause of morbidity and mortality in this population. We evaluate evidence-based management strategies including lifestyle modifications, pharmacotherapy and metabolic interventions, while emphasizing the need for multidisciplinary care. Critical gaps in risk stratification, treatment personalization, and long-term outcomes of emerging therapies are discussed, underscoring the necessity for integrated approaches to improve patient outcomes. |
| Publish Date |
2025-07-22 08:45 |
| Citation |
<p>Viet Luong T, Tran H, Hoang Thi BN, Vu HM, Le TT, Le TT, Tran Thi HT, Nguyen HM, Doan TC, Anh Ho B, Anh Hoang T, Nguyen Ngoc Dang H. Integrating liver and heart health: Cardiovascular risk reduction in patients with metabolic-associated steatotic liver disease. <i>World J Cardiol</i> 2025; 17(7): 107751</p> |
| URL |
https://www.wjgnet.com/1949-8462/full/v17/i7/107751.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v17.i7.107751 |
